The c-kit pruto-oncogene encodes a receptor tyrosine kinase that is known to play a crucial role in hematopoiesis, especially in mast cell growth and differentiation. Although a number of dominant loss-of-function mutations of c-kit gene have been well characterized in mice, rats, and humans, l i l e is known about the c-kit mutations contributing to ligandindependent activation of the c-kit receptor tyrosine kinase (KIT). In a murine mastocytoma cell line, P-815, KIT has been found to be constitutively phosphorylated on tyrosine and activated in a ligand-independent manner. Sequencing of the whole coding region of c-kit cDNA showed that c-kit cDNA of P-815 cells carries a point mutation in codon 814, resulting in amino acid substitution of Tyr for Asp. Murine HE PROTO-ONCOGENE c-kit was first identified as the cellular homologue of the oncogene v-kit present in the genome of Hardy-Zuckerman 4-feline sarcoma virus, which induces multicentric fibrosarcomas in the domestic cat.'" The c-kit gene is allelic with the dominant spotting ( W ) locus on mouse chromosome 5, and is shown to encode a receptor tyrosine kinase (RTK) that is a member of the same RTK subfamily (type I11 RTK) as the receptors for platelet-derived growth factor (PDGF), colony-stimulating factor-l (CSF-l), and vascular permeability factor/vascular endothelial growth factor.2"2 The characteristic features of this RTK subfamily are an extracellular domain made up of five Ig-like repeats, and an intracellular tyrosine kinase that is split into two domains by a hydrophilic insert seq~e n c e . *~~* l~'~ The ligand for c-kit product has been cloned and variously designated as stem cell factor (SCF), mast cell growth factor, kit ligand, or steel factor. The gene encoding SCF has been determined to reside at steel ( S ) locus on mouse chromosome 10.5.6.'3"7 A number of previous and more recent observations suggest that the KIT/SCF system plays a crucial role in hematopoiesis, melanogenesis, and garnet~genesis.~~~~'~~'* With reference to hematopoiesis, it has been shown that c-kit receptor tyrosine kinase (KIT) is expressed on mast cells and a small progenitor fraction (4%) of adult bone marrow cell^,'^-^' and that long-term culture of cord-blood or bone marrow cells with SCF results in apparently selective growth of human mast ~e l l s .~* *~~ Furthermore, it has been shown that both dominant loss-of-function mutations at WIKIT and SUSCF loci lead to deficiency of mast cells as well as severe macrothe KIT/SCF system is essential for the proliferation and differentiation of at least mast cells.
HE PROTO-ONCOGENE c-kit was first identified as the cellular homologue of the oncogene v-kit present in the genome of Hardy-Zuckerman 4-feline sarcoma virus, which induces multicentric fibrosarcomas in the domestic cat.'" The c-kit gene is allelic with the dominant spotting ( W ) locus on mouse chromosome 5, and is shown to encode a receptor tyrosine kinase (RTK) that is a member of the same RTK subfamily (type I11 RTK) as the receptors for platelet-derived growth factor (PDGF), colony-stimulating factor-l (CSF-l), and vascular permeability factor/vascular endothelial growth factor.2"2 The characteristic features of this RTK subfamily are an extracellular domain made up of five Ig-like repeats, and an intracellular tyrosine kinase that is split into two domains by a hydrophilic insert seq~e n c e . *~~* l~'~ The ligand for c-kit product has been cloned and variously designated as stem cell factor (SCF), mast cell growth factor, kit ligand, or steel factor. The gene encoding SCF has been determined to reside at steel ( S ) locus on mouse chromosome 10.5.6.'3"7 A number of previous and more recent observations suggest that the KIT/SCF system plays a crucial role in hematopoiesis, melanogenesis, and garnet~genesis.~~~~'~~'* With reference to hematopoiesis, it has been shown that c-kit receptor tyrosine kinase (KIT) is expressed on mast cells and a small progenitor fraction (4%) of adult bone marrow cell^,'^-^' and that long-term culture of cord-blood or bone marrow cells with SCF results in apparently selective growth of human mast ~e l l s .~* *~~ Furthermore, it has been shown that both dominant loss-of-function mutations at WIKIT and SUSCF loci lead to deficiency of mast cells as well as severe macrothe KIT/SCF system is essential for the proliferation and differentiation of at least mast cells.
Several lines of evidences suggested that RTKs encoded by proto-oncogenes can function as oncogenic proteins and play causal roles in cell transformation.lo*ll For example, the "activating" mutations of proto-oncogene c-fms were reported to induce morphologic transformation, anchorageindependent growth, and tumorgenecity in mouse National Institutes of Health (NIH)/3T3 cells. 26 abberant differentiation, and neoplastic transformation of the cells expressing KIT. However, all of the c-kit mutations so far described in mice, rats, and humans have been reported to result in a decrease in c-kit tyrosine kinase a~tivity:"~' with the exception of a single instance of a human mast cell leukemia cell line, HMC-1, in which KIT is constitutively activated by two point mutations, particularly by amino acid substitution of Val for Asp in codon 816.32
In the present study, we took advantage of molecular analyses in a murine mastocytoma cell line, P-815, that has been reported to exhibit constitutive phosphorylation on tyrosine of KIT in the absence of stimulation with SCF.33 Interestingly, a single point mutation in the codon 8 14, resulting in amino acid substitution of Tyr for Asp, was observed in c-kit cDNA of P-815 cells. Furthermore the mutant-form of murine K I T T Y r s l 4 was found to be constitutively activated in cells of a human embryonic kidney cell line, 293T, into which a mutant-type ckit cDNA encoding Tyr in codon 8 14 (hereafter called kit'^''^ cDNA) was transfected. The amino acid sequence in the region of the mutation is completely conserved in all mouse, rat, and human c-kit genes, indicating that the mutant-form of human corresponds to that of murine These results indicate that conversion of AspBL4 to either ValBL4 or Ty?' is an activating mutation of murine KIT, and provide a hypothesis that "the codon 814 mutations" may contribute to transformation of mast cells.
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TSUJIMURA ET AL
MATERIALS AND METHODS
Cell lines, culiured mast cells (CMCs), and mice. The P-815 cell line was originally established from a mastocytoma of a DBA/ 2 mouse by Dunn and and was supplied by the Japanese Cancer Research Bank (Tokyo, Japan). P-815 cells were adapted to grow in Dulbecco's modification of Eagle's medium (DMEM; Flow Laboratories, b i n e , UK) supplemented with 10% fetal calf serum (FCS; Nippon Bio-Supp Center, Tokyo, Japan). The NIW3T3 fihroblast cell line was generously provided by Dr S.A. Aaronson (National Cancer Institute, Bethesda, MD). The WC-SWSU3T3-l fibroblast cell line was established in our laboratory, as described p r e v i o~s l y .~~ A human embryonic kidney cell line, 293T, was provided by Dr D. Baltimore (Rockefeller University, New York, NY), and was derived from human embryonic kidney cells transformed by DNA from human adenovirus type 5.36 2937 cells were maintained in DMEM supplemented with 10% FCS. To obtain CMCs, normal C57BL/6-+/+ mice of 5 days of age were killed by overinhalation of ether. Spleens were removed and cells were suspended as described p r e v i~u s l y .~~ Pokeweed mitogen-stimulated spleen cell conditioned medium (PWM-SCM) was prepared according to the method described by Nakahata et aL3' Culture flasks (Nunc, Roskilde, Denmark) containing 2 X IO' spleen cells and 5 mL Qminimal essential medium (Q-MEM; Flow Laboratories) supplemented with m o a 2-mercaptcethanol, 10% PWM-SCM, and 10% FCS were incubated at 37°C in a humidified atmosphere of 5% CO, in air. Half of the medium was replaced every 7 days, and more than 95% of cells were CMCs at 4 weeks after the initiation of the culture.39 Normal DBA/2-+/+ mice were kindly provided by Dr T. Nomura (Osaka University, Osaka, Japan).
FZow cytometry. Preparation and specificity of the ACK2 rat monoclonal antibody (MoAb) against the extracellular domain of KIT have been described in CMCs and P-815 cells were incubated first with ACK2 MoAb at 4°C for 30 minutes, rinsed, and then stained with fluorescein isothiocyanate (F1TC)-conjugated rabbit antirat Ig antibody (DAKO AIS, Glostrup, Denmark). Cells were rinsed and analyzed on a FACScan (Becton Dickinson, Los Angeles, CA).
Immunoprecipitation and immunoblotting. The procedures of cell lysis, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and immunoblotting were performed according to the methods described previously?'" Briefly, exponentially growing CMCs, P-81.5 cells, and transfected cells were washed free of serum and growth factors and incubated in serum-free ASF-102 medium (Ajinomoto, Tokyo, Japan) for 4 hours at 37°C to factor-deprive the cells. The cells (IO7 cells suspended in 1 mL of ASF-102) were then exposed to 100 ng/mL of recombinant mouse SCF (rmSCF; a gift from Kirin Brewery Company Ltd, Tokyo, Japan) for 15 minutes at 37°C. After stimulation, cells were lysed in lysis buffer (20 mm011 L Tris-HCI [pH 8.01, 137 mmolL NaCI, 10% glycerol, 1% Nonidet P-40, and protease and phosphatase inhibitors) at 4°C for 20 minutes. The extracts were precipitated with ACK2 MoAb and protein-G Sepharose beads (Pharmacia, Uppsala, Sweden). The immunoprecipitates were washed with lysis buffer and were subjected to SDS-PAGE with 6% polyacrylamide. Proteins were electrophoretically transferred from the gel onto a polyvinylidene difluoride membrane (Immobilon; Millipore Corp, Bedford, MA), and immunoblotting was performed with antiphosphotyrosine antibody. The antiphosphotyrosine antibody, a murine MoAb generated against phosphotyramine, was generously supplied by Dr B. Druker (Dana-Farber Cancer Institute, Boston, MA).
Immune complex kinase assay. The cell lysates were prepared using lysis buffeZ7," and incubated for 45 minutes at 4°C with a rabbit polyclonal antibody to the whole murine KIT (a generous gift of Dr P. Besmer, Cornell University Graduate School of Medical In addition to the abovementioned oligonucleotide primers, the following oligonucleotide prirners were also synthesized for the determination of nucleotide sequence: cDNA synthesis, isolation of PCR-amplijied products, and sequencing of c-kit cDNA. Total RNA was extracted from P-815 cells and the cerebellums of DBA/2-+/+ mice using the guanidme isothiocyanate method.= From 5 pg of total RNA, the single-strand cDNA was synthesized using reverse-transcriptase and downstream antisense primers. cDNA was amplified by PCR using Taq DNA polymerase in 30 cycles of 1 minute of denaturation at 94°C 2 minutes of annealing at 5 5 T , and 3 minutes of synthesis at 72°C.47 For the analysis of DNA sequence, products of reverse-transcriptase modification of PCR (RT-PCR) were gel-purified and then treated with T4 polynucleotide kinase and Klenow fragment of DNA polymerase I. The products were subcloned into the EcoRV site of Bluescript I KS(-) (Stratagene, La Jolla, CA). tion method?' Purified DNAs were digested with Pst I, EcoRI, or Bgl I1 and then was subjected to 1% agarose electropheresis. The mouse c-kit cDNA (nucleotides 1 to 371 I ) was used as a probe after labeling with [."P]-(Y-~CTP (DuPonmEN; 10 mCilmL) by random oligonucleotide priming. Construction of transgene and transfection. The gene encoding murine wild-type c-kit cDNA (a generous gift of Dr S-l. Nishikawa, Kyoto University, Kyoto, Japan; hereafter called c-kit""" cDNA) was cloned into an EcoRV site of Bluescript I K%-). To generate c-kirTWX" cDNA, a single transversion mutation (GC +TA) at nucleotide position 2468 was introduced into c-kit"i'd cDNA by exchanging the Nhe I-Acc I fragment (nucleotide 2458 to 2650) of c-kit""" cDNA for the corresponding fragment of c-kit cDNA obtained from P-815 cells. The nucleotide numbers refer to the region of c-kit cDNA sequence reported by Qiu et al.' Preservation of the rest of the sequence was confirmed by DNA sequencing. The full coding sequences of c-kit""" cDNA or c-kitTyrni4 cDNA were then released by Hind111 and Sma I restriction digestion, isolated, and inserted into a Hindlll-Sma I site of expression vector pSV2neo'" to replace the neomycin resistance gene by c-kit""" cDNA or cDNA.
As a result, c-kit""d cDNA or kit^^'*'^ cDNA were flanked by an SV40 promoter sequence and a poly(A) site on the 5' and 3' ends, respectively. The inserts were resequenced to confirm the orientation and the mutation within the expression vectors.
The expression vectors containing c-kit""" cDNA or kit"^'^'^ cDNA were transfected into 293T cells by the calcium phosphate method as described previously." Moreover, both c-kit""d cDNA and c-kitTy'*'' cDNA were cotransfected into the cells to determine whether the conversion of Asp to Tyr in codon 814 is a dominantpositive mutation. After 40 hours of transfection, the cells were collected and used for the further analysis.
Metabolic labeling by [3SS]-methionine.
For metabolic labeling, cells were first incubated at 37°C for 2 hours in methionine-free Eagle's minimal essential medium containing 5 mmol/L glutamine, 1 mmol/L sodium pyruvate, and 10% dialyzed fetal bovine serum (Hazleton, Lenexa, KS). Cells were then incubated in the fresh medium containing ["SI-methionine (DuPonmEN; 1 0 0 pCi/mL) for 4 hours. The labeled cells were collected and lysed in lysis buffer at 4°C for 20 minutes. Radiolabeled KIT were precipitated with ACK2 MOA^'^.^' and protein-G Sepharose beads. The immunoprecipitates were washed with lysis buffer and were subjected to SDS-PAGE with 5% to 20% gradient polyacrylamide. The gel was dried and radioactive proteins were detected by autoradiography.
RESULTS
Constitutive tyrosine phosphorylation and activation of KIT in P-815 cells. The expression of KIT in P-815 cells was first examined by Row cytometry using ACK2 MoAbs that recognize the extracellular domain of murine KIT. This analysis showed that KIT was apparently expressed on the cell surface of P-815 cells at an almost similar level to that of CMCs derived from normal C57BL/6-+/+ mice (+/+ CMCs) (Fig IA) .
We next examined the state of tyrosine phosphorylation of KIT in P-815 cells before and after stimulation with rmSCF. P-815 cells and +/+ CMCs were removed from growth factors for 4 hours and then stimulated with 1 0 0 ng/mL of rmSCF for 15 minutes at 37'C. KIT was then immunoprecipitated, and changes in tyrosine phosphorylation were detected by immunoblotting using a specific MoAb for phosphotyrosine. In accord with the previous finding of Rottapel et the immunoblotting analysis demonstrated that KIT was strikingly phosphorylated on tyrosine residues KIT was immunoprecipitated with a rabbit polyclonal antibody to the whole murine KIT from cell lysates before stimulation with rmSCF, and the immunoprecipitates were incubated in kinase buffer containing [yJ2P]-ATP for 20 minutes at 25°C. washed, and separated by SDS-PAGE. Incorporation of "P into KIT was visualized by autoradiography.
in P-815 cells before and after stimulation with rmSCF, whereas tyrosine phosphorylation of KIT in +/+ CMCs was observed only after treatment with rmSCF (Fig IB) .
We further examined the autokinase activity of KIT in P-815 cells. KIT was immunoprecipitated from cell lysates before stimulation with rmSCF and was subjected to immune and WC-Sl/S1/3T3-1 fibroblasts were used as positive and negative controls, respectively. SCF transcripts were not observed in P-815 cells.
complex kinase assay. Although almost equal amounts of KIT were immunoprecipitated from both samples (data not shown), KIT of P-815 cells exhibited a striking tyrosine kinase activity before stimulation with rmSCF, whereas tyrosine kinase activity of KIT in +/+ CMC was barely detectable without rmSCF stimulation (Fig 1C) .
Absence of SCF transcripts in P -S i 5 cells. To determine whether the constitutive activation of KIT in P-815 cells was induced by autocrine mechanism, the expression of SCF transcripts was examined by RT-PCR analysis in P-8 15 cells and also in NIW3T3 fibroblasts and WC-Sl/S1/3T3-1 fibroblasts generated from genetically SCF-deficient mice,"~"*" which were used as positive and negative controls, respectively. As shown in Fig 2, SCF transcripts were not observed in P-815 cells and WC-Sl/S1/3T3-1 fibroblasts, whereas a 854-bp fragment (nucleotides 180 to 1033) of SCF transcripts was easily detected in NIW3T3 fibroblasts. Moreover, we failed to detect SCF transcripts in P-8 15 cells even by RT-PCR Southern blot analysis using mouse SCF cDNA as a probe (data not shown). These results indicated that the constitutive tyrosine phosphorylation and activation of KIT in P-8 15 cells are not caused by an autocrine mechanism.
A single mutation in c-kit cDNA of P-S15 cells. The constitutive tyrosine phosphorylation and activation of KIT in P-815 cells could be explained by mutation(s) in the ckit proto-oncogene. Sequencing of the whole coding region of c-kit cDNA from P-8 15 cells showed a GC + TA transversion at nucleotide 2468, when compared with the published sequence of mouse c-kit cDNA, resulting in amino acid substitution of Tyr for Asp in codon 814. This point mutation was observed in cDNA clones generated from eight independent PCR products and was also confirmed by direct sequencing of PCR products amplified independently (Fig 3) . Because the P-8 15 cell line was established from a mastocytoma that arose in a DBA/2 mouse? the sequence of c-kit cDNA obtained from the cerebellums of DBA/2-+/+ mice was examined. As shown in Fig 3, c-kit cDNA of DBA/2-+/+ mice was found to encode Asp, but not Tyr, in codon 814, in agreement with the published sequence of c-kit cDNA of a Balb/c mouse. These results suggested that the conversion of Asp to Tyr in codon 8 14 could be a mutation, but was not a strain-specific polymorphism.
In addition, three changes caused by the strain-specific polymorphism90'32 were observed in the c-kit cDNA sequence of P-815 cells: an AT + CG transversion at nucleotide 648 that resulted in the amino acid substitution of Ala for Glu in codon 207; a CG + TA transition at nucleotide 1618 that did not induce alteration of amino acids; and a GCG codon at nucleotides 2357 to 2359 changed to a GGC codon, leading to the change from Ala to Gly in codon 777 (data not shown).
Southern blot analysis. Although sequencing analyses clearly showed that c-kit cDNA of P-815 cells had a GC + TA transversion at nucleotide 2468 resulting in amino acid substitution of Tyr for Asp in codon 814, it was not clear whether the transversion was detectable on both alleles at the WIKIT locus. Therefore, Southern blot analysis was performed on genomic DNA of P-815 cells using the murine c-kit cDNA as a probe. When genomic DNAs obtained from livers of DBA/2-+/+ mice and P-815 cells were digested with Pst I, no difference in the pattern and intensity of bands was observed (Fig 4) . However, when digested with either EcoRI or Bgl 11, genomic DNA of P-815 cells exhibited new bands that showed weaker signal magnitude than the surrounding bands and were not detectable in genomic cDNA of DBA/2-+/+ mice (Fig 4) . These results suggested that only a mutant allele with a GC -P TA transversion at nucleotide 2468 was transcribed in P-815 cells, whereas another allele was not transcribed, possibly because of a gross rearrangement of the c-kit gene.
A single point mutation leads to constitutive activation of KIT. Human SCF is known to have little effect on cells expressing murine KIT, whereas murine SCF can exert its actions through interaction with both murine and human KITS.'^.^* We therefore used human 2933 cells as recipient cells for murine c-kit cDNA transfection to examine the causal role of the point mutation in constitutive activation of KIT, this combination could disregard the effect of human SCF on murine KIT, even if SCF might be produced from 293T cells after transfection. The c-kitwi'd cDNA, c-kitTY*l4 cDNA, or both were introduced into 293T cells; wild-form KIT and mutant-form KITTyrxi4 were synthesized in 293T cells at an almost equal level (Fig 5A) . To examine the tyrosine phosphorylation and activation of KIT and KITTyrXl4 expressed in the transfected cells, they were immunoprecipitated and then subjected to immunoblotting with antiphosphotyrosine MoAb and also to immune complex kinase assay. As shown in Fig 5B, dant tyrosine phosphorylation and a striking autokinase activity were observed regardless of rmSCF stimulation ( Fig  5B and C) . These results suggested that the Asp -+ Tyr mutation may lead not only to constitutive activation of KIT but also to an increase in the intrinsic kinase activity of KIT.
DISCUSSION
Binding of a ligand to the cognate RTK triggers a series of rapid events initiating a signal cascade that leads to mitogenesis, ie, receptor dimerization, RTK-tyrosyl autophosphorylation, activation of kinase, association of RTK with its substrates such as phosphatidylinositol 3'-kinase, and phosphorylation of other cellular proteins.lo~" Thus, RTKs are normally regulated by their ligands. In addition, RTKs have been reported to be constitutively activated by a point mutation, often by multiple mutations, as well as by deletions that affect the primary structure of the protein. io,1i, 26 Comparative structure analysis of oncogene v-kit and protooncogene c-kit showed that, in oncogene v-kif, N-terminal sequences, including the transmembrane domain, and C-termina1 sequences are deleted, leaving a minimal kinase domain fused to 340 amino acids of feline leukemia virus gag.'.' These results suggest that these structural alterations are likely to be involved in oncogenic activation of v-kit, and also implicate that additional sites for KIT activation may exist in proto-oncogene c-kit. However, little is known about mutation(s) of proto-oncogene c-kit that lead to constututive, ligand-independent activation of KIT.
In this study, we have shown that KIT is phosphorylated on tyrosine residues and is activated in P-815 cells in a ligand-independent manner. These observations are consistent with the previous findings by Rottapel et al.33 Sequencing analysis of P-815 cells showed a point mutation resulting in amino acid substitution of Tyr for Asp in codon 814. To determine whether the point mutation was responsible for the constitutive tyrosine phosphorylation and activation of KIT in P-815 cells, c-kitTyr814 cDNA was transfected into cells of a human embryonic kidney cell line, 293T. In the transfected 293T cells, mutant-form was found to be strikingly phosphorylated on tyrosine and activated in the absence of rrnSCF, whereas wild-form KIT was neither phosphorylated on tyrosine nor activated unless it was stimulated by rmSCF. These results indicate that the conversion of Asp to Tyr in codon 814 is an activating mutation and plays a causal role in constitutive, ligand-independent activation of KIT in P-815 cells.
Sequencing analysis showed that no cDNA clones obtained from P-815 cells demonstrated normal c-kit sequence. In light of the data on Southern blot analysis, a gross rearrangement of c-kit gene was considered to occur in one allele. These results suggested that the only mutated allele with the Asp -+ Tyr conversion was transcribed in P-815 cells, whereas the other allele was not transcribed because of the rearrangement. To determine whether the Asp * Tyr mutation is dominant-positive, mutant-form KITTyr8I4 was coexpressed with wild-form KIT. In 2933 cells transfected either with c-kitSr814 cDNA alone or with both kit^^'^ cDNA and c-kitwiId cDNA, an abundant tyrosine phosphorylation and a striking autokinase activity were observed, regardless of rmSCF stimulation. These results suggested that the Asp + Tyr conversion is a dominant-positive activating mutation.
An activating mutation in codon 816 of human KIT, corresponding to codon 814 of mouse KIT, was also detected in a human mast-cell leukemia cell line, HMC-1.32 We have recently shown that c-kit genes of HMC-l cells were composed of a normal allele and a mutant allele with two point mutations in codon 560 (GTT + GTC) and codon 8 16 (GAC + GTC), resulting in intracellular amino acid substitutions of Gly for Val and Val for Asp, respectively. When mutanttype murine c-kit cDNAs encoding Gly559 and/or VaP4, corresponding to human Gly560 and/or Valsi6, were expressed in 293T cells, mutant-form KITG'ys59*Vd814 or was phosphorylated on tyrosine and activated at equally high levels even in the absence of rmSCF, whereas tyrosine phosphorylation and activation of mutant-form K I P y " 9 or wildform KIT was modest or slight, re~pectively.~' These results indicated that a murine Asp8I4 + Va1814 mutation, corresponding to a human Asp''' + Valsi6 mutation, may be a dominant-positive activating mutation. Taking these facts together, it is suggested that constitutive activation of KIT can result from a single amino-acid replacement of Asp by either Val or Tyr in codon 8 14, and that codon 814 of murine c-kit gene may be a "hot spot" for activating mutation.
Although the constitutive activation of KIT caused by the codon 814 mutations within the tyrosine kinase domain are dramatic, the oncogenic potential or the biologic effect of these mutations has yet to be clarified. This question is currently being examined by transfection of mutant-type c-kit cDNA into hematopoietic stem cells or factor-dependent hematopoietic cell lines, and these examinations could provide insights into the biologic significance of the mutations. However, it is important to note that the two types of cells bearing the activating mutations of c-kit gene are both neoplastic mast cells. Given the fact that KIT is implicated as an indispensable molecule for the proliferation and differentiation of mast cells~~6~'2~'8~24~27-31 these results raise the possibility that the codon 814 mutations may be at least partially involved in neoplastic growth or oncogenesis of mast cells. The extensive surveys on de novo mast-cell neoplasmas might be helpful to show whether the codon 814 mutations contribute to the development of mast-cell malignancies.
In addition to mast-cell malignancies, it has been suggested that KIT or c-kit mRNA has been detected in a variety of neoplastic cells. For example, we and others have reported that KIT is expressed in human leukemia cell lines of erythroid and megakaryocytic lineages, and also in most cases of human acute myeloblastic leukemia cells and some cases of chronic myelogenous leukemia in blastic crisis.43.44.53-57 Also, KIT has been reported to be expressed in testicular germ cell tumors and small-cell lung cancer^.^'.^^ It is therefore possible that, if present, the codon 814 mutation of ckit might etiologically contribute to various malignancies other than those of mast cells.
Although the codon 814 mutations seem not only to constitutively activate KIT but also to increase the intrinsic kinase activity of KIT, the underlying mechanism(s) whereby the mutations leads to ligand-independent activation of KIT ACTIVATING MUTATION OF MURINE c-kit 2625 is not known at this time. However, it may be important to note that the amino acid sequence of the region in KIT tyrosine kinase domain is widely conserved in many other RTKs such as receptors for PDGF, CSF-1, insulin, and hepatic growth factor.@" Therefore, it is possible that the amino acid sequence of the Asp814 region may have an essential role in the structure and function of many RTKs. If so, the conversion of Asp to either Tyr or Val in codon 814 might induce a conformational change of KIT, thereby leading to receptor dimerization that is thought to be essential for RTK activation. Also, it is possible that similar mutations in other RTKs might yield activating variants as well and participate in the development of a variety of malignancies.
Further studies on c-kit mutants will not only provide important insight into the fundamental mechanism(s) underlying regulation of normal cell growth but will also provide further understanding of oncogenesis mediated by RTKs.
